|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Portolani N, Coniglio A, Ghidoni S,
Giovanelli M, Benetti A, Tiberio GA and Giulini SM: Early and late
recurrence after liver resection for hepatocellular carcinoma:
Prognostic and therapeutic implications. Ann Surg. 243:229–235.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forner A, Hessheimer AJ, Isabel Real M and
Bruix J: Treatment of hepatocellular carcinoma. Crit Rev Oncol
Hematol. 60:89–98. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pellikainen J, Naukkarinen A, Ropponen K,
Rummukainen J, Kataja V, Kellokoski J, Eskelinen M and Kosma VM:
Expression of HER2 and its association with AP-2 in breast cancer.
Eur J Cancer. 40:1485–1495. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pellikainen JM and Kosma VM: Activator
protein-2 in carcinogenesis with a special reference to breast
cancer - a mini review. Int J Cancer. 120:2061–2067. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ropponen KM, Kellokoski JK, Lipponen PK,
Pietiläinen T, Eskelinen MJ, Alhava EM and Kosma VM: p22/WAF1
expression in human colorectal carcinoma: Association with p53,
transcription factor AP-2 and prognosis. Br J Cancer. 81:133–140.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ruiz M, Pettaway C, Song R, Stoeltzing O,
Ellis L and Bar-Eli M: Activator protein 2alpha inhibits
tumorigenicity and represses vascular endothelial growth factor
transcription in prostate cancer cells. Cancer Res. 64:631–638.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schwartz B, Melnikova VO, Tellez C,
Mourad-Zeidan A, Blehm K, Zhao YJ, McCarty M, Adam L and Bar-Eli M:
Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9
and an increase in tumorigenicity of colon cancer cells in vivo.
Oncogene. 26:4049–4058. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tellez C, McCarty M, Ruiz M and Bar-Eli M:
Loss of activator protein-2alpha results in overexpression of
protease-activated receptor-1 and correlates with the malignant
phenotype of human melanoma. J Biol Chem. 278:46632–46642. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zeng YX, Somasundaram K and el-Deiry WS:
AP2 inhibits cancer cell growth and activates p21WAF1/CIP1
expression. Nat Genet. 15:78–82. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bar-Eli M: Gene regulation in melanoma
progression by the AP-2 transcription factor. Pigment Cell Res.
14:78–85. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang S, Jean D, Luca M, Tainsky MA and
Bar-Eli M: Loss of AP-2 results in downregulation of c-KIT and
enhancement of melanoma tumorigenicity and metastasis. EMBO J.
17:4358–4369. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anttila MA, Kellokoski JK, Moisio KI,
Mitchell PJ, Saarikoski S, Syrjänen K and Kosma VM: Expression of
transcription factor AP-2alpha predicts survival in epithelial
ovarian cancer. Br J Cancer. 82:1974–1983. 2000.PubMed/NCBI
|
|
14
|
Heimberger AB, McGary EC, Suki D, Ruiz M,
Wang H, Fuller GN and Bar-Eli M: Loss of the AP-2alpha
transcription factor is associated with the grade of human gliomas.
Clin Cancer Res. 11:267–272. 2005.PubMed/NCBI
|
|
15
|
Karjalainen JM, Kellokoski JK, Eskelinen
MJ, Alhava EM and Kosma VM: Downregulation of transcription factor
AP-2 predicts poor survival in stage I cutaneous malignant
melanoma. J Clin Oncol. 16:3584–3591. 1998.PubMed/NCBI
|
|
16
|
Lipponen P, Aaltomaa S, Kellokoski J,
Ala-Opas M and Kosma V: Expression of activator protein 2 in
prostate cancer is related to tumor differentiation and cell
proliferation. Eur Urol. 37:573–578. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ropponen KM, Kellokoski JK, Pirinen RT,
Moisio KI, Eskelinen MJ, Alhava EM and Kosma VM: Expression of
transcription factor AP-2 in colorectal adenomas and
adenocarcinomas; comparison of immunohistochemistry and in situ
hybridisation. J Clin Pathol. 54:533–538. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ding X, Yang Z, Zhou F, Wang F, Li X, Chen
C, Li X, Hu X, Xiang S and Zhang J: Transcription factor AP-2α
regulates acute myeloid leukemia cell proliferation by influencing
Hoxa gene expression. Int J Biochem Cell Biol. 45:1647–1656. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oyama N, Takahashi H, Tojo M, Iwatsuki K,
Iizuka H, Nakamura K, Homma Y and Kaneko F: Different properties of
three isoforms (alpha, beta, and gamma) of transcription factor
AP-2 in the expression of human keratinocyte genes. Arch Dermatol
Res. 294:273–280. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bennett KL, Romigh T and Eng C: AP-2alpha
induces epigenetic silencing of tumor suppressive genes and
microsatellite instability in head and neck squamous cell
carcinoma. PLoS One. 4:e69312009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stabach PR, Thiyagarajan MM, Woodfield GW
and Weigel RJ: AP2alpha alters the transcriptional activity and
stability of p53. Oncogene. 25:2148–2159. 2006. View Article : Google Scholar
|
|
22
|
Shi D, Xie F, Zhang Y, Tian Y, Chen W, Fu
L, Wang J, Guo W, Kang T, Huang W, et al: TFAP2A regulates
nasopharyngeal carcinoma growth and survival by targeting HIF-1α
signaling pathway. Cancer Prev Res (Phila). 7:266–277. 2014.
View Article : Google Scholar
|
|
23
|
Li Q and Dashwood RH: Activator protein
2alpha associates with adenomatous polyposis coli/beta-catenin and
Inhibits beta-catenin/T-cell factor transcriptional activity in
colorectal cancer cells. J Biol Chem. 279:45669–45675. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wajapeyee N, Britto R, Ravishankar HM and
Somasundaram K: Apoptosis induction by activator protein 2alpha
involves transcriptional repression of Bcl-2. J Biol Chem.
281:16207–16219. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, Zhou
C and Zhou J: A miR-200b/200c/429-binding site polymorphism in the
3′ untranslated region of the AP-2α gene is associated with
cisplatin resistance. PLoS One. 6:e290432011. View Article : Google Scholar
|
|
26
|
Wajapeyee N, Raut CG and Somasundaram K:
Activator protein 2alpha status determines the chemosensitivity of
cancer cells: Implications in cancer chemotherapy. Cancer Res.
65:8628–8634. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Douglas DB, Akiyama Y, Carraway H,
Belinsky SA, Esteller M, Gabrielson E, Weitzman S, Williams T,
Herman JG and Baylin SB: Hypermethylation of a small CpGuanine-rich
region correlates with loss of activator protein-2alpha expression
during progression of breast cancer. Cancer Res. 64:1611–1620.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li M, Li X, Wang E and Luo E: Upregulation
of Toll-like receptor 2 gene expression by acetylation of AP-2
alpha in THP-1 cells, a human monocytic cell line. Int J Biochem
Cell Biol. 45:1594–1599. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ding X, Zhou F, Wang F, Yang Z, Zhou C,
Zhou J, Zhang B, Yang J, Wang G, Wei Z, et al: Eps8 promotes
cellular growth of human malignant gliomas. Oncol Rep. 29:697–703.
2013.
|
|
30
|
Chen C, Liang Z, Huang W, Li X, Zhou F, Hu
X, Han M, Ding X and Xiang S: Eps8 regulates cellular proliferation
and migration of breast cancer. Int J Oncol. 46:205–214. 2015.
|
|
31
|
Ding X, Fan C, Zhou J, Zhong Y, Liu R, Ren
K, Hu X, Luo C, Xiao S, Wang Y, et al: GAS41 interacts with
transcription factor AP-2beta and stimulates AP-2beta-mediated
transactivation. Nucleic Acids Res. 34:2570–2578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li X, Chen C, Wang F, Huang W, Liang Z,
Xiao Y, Wei K, Wan Z, Hu X, Xiang S, et al: KCTD1 suppresses
canonical Wnt signaling pathway by enhancing β-catenin degradation.
PLoS One. 9:e943432014. View Article : Google Scholar
|
|
33
|
Shekhani MT, Jayanthy AS, Maddodi N and
Setaluri V: Cancer stem cells and tumor transdifferentiation:
Implications for novel therapeutic strategies. Am J Stem Cells.
2:52–61. 2013.PubMed/NCBI
|
|
34
|
Lobo NA, Shimono Y, Qian D and Clarke MF:
The biology of cancer stem cells. Annu Rev Cell Dev Biol.
23:675–699. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tang KH, Ma S, Lee TK, Chan YP, Kwan PS,
Tong CM, Ng IO, Man K, To KF, Lai PB, et al: CD133(+) liver
tumor-initiating cells promote tumor angiogenesis, growth, and
self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
Hepatology. 55:807–820. 2012. View Article : Google Scholar
|
|
36
|
Zhang W and Liu HT: MAPK signal pathways
in the regulation of cell proliferation in mammalian cells. Cell
Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cui J, Dong BW, Liang P, Yu XL and Yu DJ:
Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of
hepatocellular carcinoma patients undergoing tumor resection. World
J Gastroenterol. 10:1533–1536. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lustig B and Behrens J: The Wnt signaling
pathway and its role in tumor development. J Cancer Res Clin Oncol.
129:199–221. 2003.PubMed/NCBI
|
|
39
|
Willert K, Brown JD, Danenberg E, Duncan
AW, Weissman IL, Reya T, Yates JR III and Nusse R: Wnt proteins are
lipid-modified and can act as stem cell growth factors. Nature.
423:448–452. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wong CM, Fan ST and Ng IO: beta-Catenin
mutation and over-expression in hepatocellular carcinoma:
Clinicopathologic and prognostic significance. Cancer. 92:136–145.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zeng G, Apte U, Cieply B, Singh S and
Monga SP: siRNA-mediated beta-catenin knockdown in human hepatoma
cells results in decreased growth and survival. Neoplasia.
9:951–959. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Soussi T and Béroud C: Assessing TP53
status in human tumours to evaluate clinical outcome. Nat Rev
Cancer. 1:233–240. 2001. View Article : Google Scholar
|
|
43
|
McPherson LA, Loktev AV and Weigel RJ:
Tumor suppressor activity of AP2alpha mediated through a direct
interaction with p53. J Biol Chem. 277:45028–45033. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Thiery JP: Epithelial-mesenchymal
transitions in development and pathologies. Curr Opin Cell Biol.
15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Thomas GJ, Lewis MP, Hart IR, Marshall JF
and Speight PM: AlphaVbeta6 integrin promotes invasion of squamous
carcinoma cells through up-regulation of matrix
metalloproteinase-9. Int J Cancer. 92:641–650. 2001. View Article : Google Scholar : PubMed/NCBI
|
